{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:09:54Z","timestamp":1791266994943,"version":"4.1.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ctrv.2021.102280","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T11:40:47Z","timestamp":1629286847000},"page":"102280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8033-4945","authenticated-orcid":false,"given":"Michela","family":"Giustozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8343-4888","authenticated-orcid":false,"given":"Cecilia","family":"Becattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Roila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Agnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Mandal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ctrv.2021.102280_b0005","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.ctrv.2021.102280_b0010","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/d41573-019-00167-9","article-title":"Immuno-oncology drug development goes global","volume":"18","author":"Xin","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"26","key":"10.1016\/j.ctrv.2021.102280_b0015","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102280_b0020","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrclinonc.2015.209","article-title":"Combination cancer immunotherapies tailored to the tumour microenvironment","volume":"13","author":"Smyth","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"9948","key":"10.1016\/j.ctrv.2021.102280_b0025","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102280_b0035","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2021.102280_b0040","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2021.102280_b0045","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102280_b0050","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/ATVBAHA.111.224709","article-title":"Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation","volume":"31","author":"Bu","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"10.1016\/j.ctrv.2021.102280_b0055","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood-2018-11-882993","article-title":"Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms","volume":"133","author":"Jackson","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2021.102280_b0060","doi-asserted-by":"crossref","unstructured":"Mandala M, Falanga A, Roila F, Group EGW. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22 Suppl 6:vi85-92.","DOI":"10.1093\/annonc\/mdr392"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102280_b0065","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1160\/TH16-08-0615","article-title":"Cancer-associated venous thromboembolism: Burden, mechanisms, and management","volume":"117","author":"Ay","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ctrv.2021.102280_b0070","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-9, W64.","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102280_b0075","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2307\/2529786","article-title":"An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"10.1016\/j.ctrv.2021.102280_b0080","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 520","article-title":"Assessing risk of bias in included studies","author":"Higgins","year":"2017"},{"key":"10.1016\/j.ctrv.2021.102280_b0085","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"7414","key":"10.1016\/j.ctrv.2021.102280_b0090","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102280_b0095","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.annonc.2020.12.004","article-title":"Cobimetinib plus atezolizumab in BRAF(V600) wild-type melanoma: primary results from the randomized phase III IMspire170 study","volume":"32","author":"Gogas","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102280_b0100","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/CMR.0000000000000708","article-title":"Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)","volume":"31","author":"Hodi","year":"2021","journal-title":"Melanoma Res"},{"issue":"13","key":"10.1016\/j.ctrv.2021.102280_b0105","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1158\/1078-0432.CCR-19-3936","article-title":"A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma","volume":"26","author":"Postow","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102280_b0110","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/COC.0000000000000644","volume":"43","author":"Markovic","year":"2020","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2021.102280_b0115","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1200\/JCO.19.01381","article-title":"Phase III Study of Adjuvant Ipilimumab (3 or 10 mg\/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609","volume":"38","author":"Tarhini","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2021.102280_b0120","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102280_b0125","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2021.102280_b0130","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2018.09.025","article-title":"Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study","volume":"105","author":"Namikawa","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2021.102280_b0135","doi-asserted-by":"crossref","unstructured":"Davar D, Wang H, Chauvin JM, Pagliano O, Fourcade JJ, Ka M, et al. Phase Ib\/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. J Clin Oncol. 2018:JCO1800632.","DOI":"10.1200\/JCO.18.00632"},{"issue":"11","key":"10.1016\/j.ctrv.2021.102280_b0140","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102280_b0145","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2021.102280_b0150","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3389\/fonc.2018.00044","article-title":"Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma","volume":"8","author":"Mullinax","year":"2018","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102280_b0155","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/1346-8138.14227","article-title":"Safety and efficacy of nivolumab in Japanese patients with malignant melanoma: An interim analysis of a postmarketing surveillance","volume":"45","author":"Kiyohara","year":"2018","journal-title":"J Dermatol"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102280_b0160","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102280_b0165","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40425-017-0290-x","article-title":"Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin\/paclitaxel in unresectable stage III or stage IV melanoma","volume":"5","author":"Jamal","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102280_b0170","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00280-016-3237-x","article-title":"Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)","volume":"79","author":"Yamazaki","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"10.1016\/j.ctrv.2021.102280_b0175","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.ctrv.2021.102280_b0180","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1001\/jama.2014.13943","article-title":"Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial","volume":"312","author":"Hodi","year":"2014","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102280_b0185","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102280_b0190","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","article-title":"Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma","volume":"31","author":"Ribas","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102280_b0195","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102280_b0200","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1158\/1078-0432.CCR-10-2463","article-title":"Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc\/IV melanoma","volume":"17","author":"Sarnaik","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102280_b0205","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10637-009-9376-8","article-title":"A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma","volume":"29","author":"Hersh","year":"2011","journal-title":"Invest New Drugs"},{"issue":"7","key":"10.1016\/j.ctrv.2021.102280_b0210","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/cncr.24951","article-title":"Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival","volume":"116","author":"Ku","year":"2010","journal-title":"Cancer"},{"issue":"36","key":"10.1016\/j.ctrv.2021.102280_b0215","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1200\/JCO.2008.16.1927","article-title":"Phase I\/II study of ipilimumab for patients with metastatic melanoma","volume":"26","author":"Weber","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102280_b0220","doi-asserted-by":"crossref","unstructured":"Boyer M, Sendur MAN, Rodriguez-Abreu D, Park K, Lee DH, Cicin I, et al. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >\/= 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. J Clin Oncol. 2021:JCO2003579.","DOI":"10.1200\/JCO.20.03579"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102280_b0225","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2021.102280_b0230","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/ijc.33399","article-title":"Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study","volume":"148","author":"Wu","year":"2021","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102280_b0235","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jtho.2020.10.004","article-title":"Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC","volume":"16","author":"Herbst","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"22","key":"10.1016\/j.ctrv.2021.102280_b0240","doi-asserted-by":"crossref","first-page":"8406","DOI":"10.1002\/cam4.3456","article-title":"Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer","volume":"9","author":"Tfayli","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2021.102280_b0245","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ejca.2020.06.007","article-title":"Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric\/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia\/b study (JVDJ)","volume":"137","author":"Bang","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2021.102280_b0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2020.02.016","article-title":"A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226","volume":"143","author":"Juergens","year":"2020","journal-title":"Lung Cancer"},{"issue":"14","key":"10.1016\/j.ctrv.2021.102280_b0255","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1200\/JCO.19.02446","article-title":"Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1Positive, Advanced NonSmall-Cell Lung Cancer in the KEYNOTE-010 Study","volume":"38","author":"Herbst","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102280_b0260","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.lungcan.2020.02.003","article-title":"Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer","volume":"142","author":"Besse","year":"2020","journal-title":"Lung Cancer"},{"issue":"21","key":"10.1016\/j.ctrv.2021.102280_b0265","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ctrv.2021.102280_b0270","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1158\/1078-0432.CCR-19-1305","article-title":"Phase I\/Ib Study of Pembrolizumab Plus Vorinostat in Advanced\/Metastatic Non-Small Cell Lung Cancer","volume":"25","author":"Gray","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102280_b0275","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(19)30458-9","article-title":"Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a\/b trial","volume":"20","author":"Herbst","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2021.102280_b0280","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2019.05.001","article-title":"Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial","volume":"133","author":"Peters","year":"2019","journal-title":"Lung Cancer"},{"issue":"10183","key":"10.1016\/j.ctrv.2021.102280_b0285","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102280_b0290","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000500571","article-title":"A Phase 1b\/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors","volume":"97","author":"Hong","year":"2019","journal-title":"Oncology"},{"issue":"24","key":"10.1016\/j.ctrv.2021.102280_b0295","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ctrv.2021.102280_b0300","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ctrv.2021.102280_b0305","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S1470-2045(18)30673-9","article-title":"Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study","volume":"19","author":"Barlesi","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2021.102280_b0310","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.lungcan.2018.05.023","article-title":"Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy","volume":"122","author":"Lee","year":"2018","journal-title":"Lung Cancer"},{"issue":"22","key":"10.1016\/j.ctrv.2021.102280_b0315","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102280_b0320","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","article-title":"ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial","volume":"19","author":"Wrangle","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102280_b0325","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","article-title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study","volume":"19","author":"Garassino","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102280_b0330","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jtho.2018.02.022","article-title":"Phase 1\/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)","volume":"13","author":"Spigel","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"20","key":"10.1016\/j.ctrv.2021.102280_b0335","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ctrv.2021.102280_b0340","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102280_b0345","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/annonc\/mdx008","article-title":"Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial","volume":"28","author":"Hui","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2021.102280_b0350","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1470-2045(17)30240-1","article-title":"Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial","volume":"18","author":"Gulley","year":"2017","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102280_b0355","first-page":"e000108","article-title":"Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer","volume":"1","author":"Nishio","year":"2016","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102280_b0360","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2021.102280_b0365","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.ctrv.2021.102280_b0370","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ctrv.2021.102280_b0375","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.ctrv.2021.102280_b0380","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study","volume":"30","author":"Lynch","year":"2012","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ctrv.2021.102280_b0385","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl_4","key":"10.1016\/j.ctrv.2021.102280_b0390","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2021.102280_b0395","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.thromres.2020.09.038","article-title":"Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review","volume":"196","author":"Solinas","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.ctrv.2021.102280_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2021.02.002","article-title":"Increased incidence of venous thromboembolism with cancer immunotherapy","author":"Roopkumar","year":"2021","journal-title":"Med"},{"issue":"12","key":"10.1016\/j.ctrv.2021.102280_b0405","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1182\/blood.2020007878","article-title":"Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy","volume":"137","author":"Moik","year":"2021","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.ctrv.2021.102280_b0410","doi-asserted-by":"crossref","first-page":"e10772","DOI":"10.1097\/MD.0000000000010772","article-title":"Pembrolizumab-induced acute thrombosis: A case report","volume":"97","author":"Kunimasa","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.ctrv.2021.102280_b0415","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001719","article-title":"Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival","volume":"9","author":"Sussman","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2021.102280_b0420","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s10637-019-00881-6","article-title":"Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors","volume":"38","author":"Ando","year":"2020","journal-title":"Invest New Drugs"},{"issue":"2","key":"10.1016\/j.ctrv.2021.102280_b0425","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/jth.15175","article-title":"Discordant reporting of VTE in pancreatic cancer: A systematic review and meta-analysis of thromboprophylaxis versus chemotherapeutic trials","volume":"19","author":"Chiasakul","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1016\/j.ctrv.2021.102280_b0430","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMe1816060","article-title":"Direct Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with Cancer","volume":"380","author":"Agnelli","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737221001286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737221001286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:26:16Z","timestamp":1759656376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737221001286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":85,"alternative-id":["S0305737221001286"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2021.102280","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2021.102280","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102280"}}